Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opus forms epileptic drug monitoring deal:

This article was originally published in Clinica

Executive Summary

Opus Diagnostics has entered into an exclusive licence agreement with Dainippon Pharmaceuticals, whereby Opus will develop a diagnostic test to monitor blood levels of the anti-epileptic drug, Zonisamide. The test is expected to monitor levels of the drug in selected patients in order to help physicians optimise dosage and patient outcomes. Zonisamide, developed by Osaka, Japan-based Dainippon, is licensed in the US and Europe to Elan Pharmaceuticals. Opus, a wholly owned subsidiary of Fort Lee, New Jersey-based Caprius, says it is investigating other opportunities of co-operation with Dainippon in the diagnostics field.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067510

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel